RhumbLine Advisers’s Climb Bio CLYM Stock Holding History
Bought
Maintained
Sold
Other funds holding CLYM
RhumbLine Advisers's CLYM Position: Q3 2026 in Review
RhumbLine Advisers increased its Climb Bio (CLYM) stake by 10% in Q3 2026, buying an estimated $61.8K and bringing the position to 48,979 shares worth $562K. The position accounts for ﹤0.01% of the portfolio, ranked #2653.
RhumbLine Advisers first reported a position in CLYM in Q2 2024 and has held it in 6 quarters since. The position peaked at $581K in Q2 2026. 128 funds tracked by Wall St. Rank hold CLYM as of Q3 2026.
- RhumbLine Advisers held 48,979 shares of Climb Bio worth $562K as of Q3 2026.
- RhumbLine Advisers bought 4,435 Climb Bio shares in Q3 2026, an estimated $61.8K.
- Climb Bio made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2653 holding.
- RhumbLine Advisers first reported a position in Climb Bio in Q2 2024 and has held it in 6 quarters since.
- RhumbLine Advisers's Climb Bio position peaked at $581K in Q2 2026.
- 128 funds tracked by Wall St. Rank held Climb Bio as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.